Acute respiratory distress syndrome, also known as ARDS, is a common killer among critically ill patients hospitalized with COVID-19. But even if they survive, it’s a long road to recovery.

Researchers observed high lysolipid levels in those with acute respiratory distress syndrome (ARDS), which may lead to the condition. More research is needed on ARDS to find the best treatments.

Acute Respiratory Distress Syndrome (ARDS) Detailed Epidemiology Segmentation. In the 7MM, the total incident population of ARDS is estimated to be 799,872, in 2017.

Acute respiratory distress syndrome (ARDS) is an emergency situation in both children and adults, as it compromises the vital oxygen supply to the body. A new study published in JAMA Network Open ...

Acute respiratory distress syndrome (ARDS) is a devastating complication of infection or injury, caused by out-of-control inflammation in the lungs. The COVID-19 pandemic brought the need for ARDS ...

Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. Understanding the rapid ...

Of the more than 13,000 children who survived acute respiratory distress syndrome (ARDS), there was a 30.0% probability of hospital readmission within 1 year, 50% of which are likely to occur ...

The global acute respiratory distress syndrome (ARDS) treatment market was valued at approximately USD $$ billion in 2022 and is expected to grow at a robust CAGR of more than $% during the forecast ...

InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the ...